PMEL and melanoma: In accordance with our results, Hodi et al. showed in a phase 3 study, that co-immunization with the melanoma antigen gp100 did not improve the effect of immunotherapy with the anti-CTLA-4 ipilimumab monoclonal antibody [76, 77].